RTL 02 - News: MRI and prostate ca, drug interactions, COVID, and more

Tuesday, July 21, 2020

The latest news from MDedge Hematology/Oncology:

In this episode:

  1. MRI reliably identifies significant prostate cancer
    * Original MDedge article (https://bit.ly/3hgKT1h)
    * PROMIS analysis (https://bit.ly/3fLOiEN)
  2. Drug-drug interactions to avoid in patients with GI cancer
    * Original MDedge article (https://bit.ly/39eHi0G)
  3. ctDNA clearance tracks with PFS in NSCLC subtype
    * Original MDedge article (https://bit.ly/3eJKm6o)
    * Abstract from AACR 2020 (https://bit.ly/30uQQ3R)
    * TATTON results in The Lancet Oncology (https://bit.ly/3jq1L7J)
  4. COVID-19 symptoms can linger for months
    * Original MDedge article (https://bit.ly/3eNREG0)
    * JAMA research letter (https://bit.ly/2WFS3UW)

For more MDedge Podcasts go to https://mdedge.com/podcasts/

Email the show: [email protected]

Interact with us on Twitter: @MDedgeHemOnc

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.